119 results on '"Shapiro, G.I."'
Search Results
2. Phase Ib study of eprenetapopt (APR-246) in combination with pembrolizumab in patients with advanced or metastatic solid tumors
3. Reversion and non-reversion mechanisms of resistance to PARP inhibitor or platinum chemotherapy in BRCA1/2-mutant metastatic breast cancer
4. Crizotinib in ROS1-rearranged advanced non-small-cell lung cancer (NSCLC): updated results, including overall survival, from PROFILE 1001
5. Phase I study of the checkpoint kinase 1 inhibitor GDC-0575 in combination with gemcitabine in patients with refractory solid tumors
6. Black Sea Circulation
7. Phase I safety, pharmacokinetic, and pharmacodynamic study of the oral phosphatidylinositol-3-kinase and mTOR inhibitor BGT226 in patients with advanced solid tumors
8. Safety, tolerability, pharmacokinetics and pharmacodynamics of the oral cyclin-dependent kinase inhibitor AZD5438 when administered at intermittent and continuous dosing schedules in patients with advanced solid tumours
9. 821TiP Phase I study of ceralasertib (cerala) in combination with AZD5305 in patients (pts) with advanced/metastatic ovarian cancer (OC) previously treated with PARP inhibitors (PARPis)
10. 701P NCI10221: Phase II multicenter biomarker driven combination trial of copanlisib and nivolumab in patients with molecularly-selected advanced solid tumors (BaCoN)
11. 664P Final results of a phase I/II study of combined BCL-xL and MEK inhibition with navitoclax and trametinib in KRAS or NRAS mutant advanced solid tumors
12. Formation of a dense water cascade in the marginal ice zone in the Barents Sea
13. Phase 1 safety, pharmacokinetic and pharmacodynamic study of fadraciclib (CYC065), a cyclin dependent kinase inhibitor, in patients with advanced cancers (NCT02552953)
14. Black Sea Circulation
15. Randomized phase II (RP2) study of ATR inhibitor M6620 in combination with gemcitabine versus gemcitabine alone in platinum-resistant high grade serous ovarian cancer (HGSOC)
16. A phase I open label dose escalation trial evaluating VT1021 in patients with advanced solid tumours
17. A phase IIa clinical trial combining ALRN-6924 and palbociclib for the treatment of patients with tumours harboring wild-type p53 and MDM2 amplification or MDM2/CDK4 co-amplification
18. Phase I/II study of combined BCL-XL and MEK inhibition with navitoclax (N) and trametinib (T) in KRAS or NRAS mutant advanced solid tumours
19. The Malin cascade in winter 1996
20. A young lens of Red Sea Water in the Arabian Sea
21. MA08.11 Initial Chemotherapy for Locally Advanced and Metastatic NUT Carcinoma.
22. A 2.5D model for sand transport in a shallow sea: effect of Ekman veering
23. Cascades of dense water around the world ocean
24. Neratinib in patients with HER2-mutant, metastatic cervical cancer: findings from the phase 2 SUMMIT ‘basket’ trial
25. Crizotinib in advanced ROS1-rearranged non-small cell lung cancer (NSCLC): Overall survival (OS) and updated safety from PROFILE 1001
26. Mass transport by non-linear internal waves on the Malin Shelf
27. LBA60 - Randomized phase II (RP2) study of ATR inhibitor M6620 in combination with gemcitabine versus gemcitabine alone in platinum-resistant high grade serous ovarian cancer (HGSOC)
28. 475P - A phase IIa clinical trial combining ALRN-6924 and palbociclib for the treatment of patients with tumours harboring wild-type p53 and MDM2 amplification or MDM2/CDK4 co-amplification
29. 465P - A phase I open label dose escalation trial evaluating VT1021 in patients with advanced solid tumours
30. 447PD - Phase I/II study of combined BCL-XL and MEK inhibition with navitoclax (N) and trametinib (T) in KRAS or NRAS mutant advanced solid tumours
31. A PHASE 1 STUDY OF BET INHIBITION USING RG6146 IN RELAPSED/REFRACTORY (R/R) MYC-EXPRESSING DIFFUSE LARGE B CELL LYMPHOMA (DLBCL)
32. Shipping noise in a dynamic sea: a case study of grey seals in the Celtic Sea
33. Supplementary Material for: Clinical Development of the CDK4/6 Inhibitors Ribociclib and Abemaciclib in Breast Cancer
34. 484 Treatment of advanced solid tumors with golvatinib (E7050) in combination with lenvatinib (E7080)
35. 238 Reversal of primary and acquired PARP-inhibitor resistance in BRCA-mutated triple-negative breast cancers by inhibition of transcriptional cyclin-dependent kinases (CDKs)
36. Brentuximab Vedotin in Patients With CD30+ Mesothelioma
37. On the Evolution of Intensive Cyclonic-Anticyclonic Vortex Pairs
38. On the Dynamics of Lenslike Eddies
39. Tidally induced lateral dispersion of the Storfjorden overflow plume
40. 588 A First-in-patient Phase I Study of the Novel Gamma Secretase Inhibitor PF-03084014 in Patients with Advanced Solid Tumor Malignancies
41. 1417 POSTER A Phase II Trial of Afatinib (BIBW 2992) in Patients With Tumours Prospectively Screened for EGFR And/or HER2 Gene Amplification or EGFR Activating Mutations
42. Dense water cascading off the continental shelf
43. The alternative density structures of cold/saltwater pools on a sloping bottom: the role of friction
44. 387 First-in-human study of PF-05212384, a small molecule intravenous dual inhibitor of PI3K and mTOR in patients with advanced cancer: preliminary report on safety and pharmacokinetics
45. 651 DISCUSSION Pharmacodynamic evaluation of pCDC2 and Wee1 signature as biomarkers of target engagement for the Wee1 tyrosine kinase inhibitor MK-1775
46. 407 Phase 2 study of XL184 in a cohort of ovarian cancer patients (pts) with measurable soft tissue disease
47. 575 ALB 109564(a), a novel tubulin inhibitor: phase 1 trial in patients with solid tumours
48. G6 Clinical activity observed in a phase I dose escalation trial of an oral c-met and ALK inhibitor, PF-02341066
49. 34 ORAL Advantages of a modified continual reassessment method (CRM) for dose finding studies: experience in ongoing phase I trials with ABT-263
50. 218 POSTER A phase I dose-escalation study of the safety, pharmacokinetics and pharmacodynamics of XL147, a novel PI3K inhibitor administered orally to patients with advanced solid tumors
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.